Wendy Mao

发表

Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment

C. Drake, C. Thoburn, D. Pardoll, 2017, Cancer Immunology Research.

Differential Immune Modulation With Carbon-Ion Versus Photon Therapy.

C. Drake, C. Tsuruoka, C. Spina, 2020, International journal of radiation oncology, biology, physics.

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy

C. Drake, T. DeWeese, A. Korman, 2018, Clinical Cancer Research.

Overcoming current challenges to T-cell receptor therapy via metabolic targeting to increase antitumor efficacy, durability, and tolerability

Wendy Mao, 2022, Frontiers in Immunology.

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition

C. Drake, S. Yegnasubramanian, A. Ghasemzadeh, 2019, Journal of Immunotherapy for Cancer.

Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses

Xinzheng V. Guo, Hu Li, C. Drake, 2020, Clinical Cancer Research.

Immunotherapy for Prostate Cancer: An Evolving Landscape

C. Drake, Wendy Mao, 2018 .

Strategies for improving antitumor response in prostate cancer: BET Bromodomain inhibition and A2A Adenosine Receptor inhibition as methods of targeting prostate cancer

Wendy Mao, 2019 .

Preclinical development of combination therapy targeting the dominant cytokine interleukin-1β for renal cell carcinoma.

Hu Li, C. Drake, A. Ghasemzadeh, 2019, Journal of Clinical Oncology.

Radiation Induces a Dose-Dependent Increase in Immunosuppressive Myeloid Cells in Solid Tumors

C. Drake, C. Spina, D. Aggen, 2019, International Journal of Radiation Oncology, Biology, Physics.

SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion

Tarun S. Nambiar, Samuel B. Hayward, Alberto Ciccia, 2024, Cell.

Abstract B032: Combined A2AR and PARP inhibition in homologous recombination deficient (HRD) castrate-resistant prostate cancer (CRPC)

C. Drake, S. Bansal, P. McCann, 2023, Cancer Research.